These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34697111)

  • 1. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
    Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
    BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
    Bahardoust M; Mokhtare M; Barati M; Bagheri-Hosseinabadi Z; Karimi Behnagh A; Keyvani H; Agah S
    J Infect Chemother; 2020 Dec; 26(12):1265-1271. PubMed ID: 32762882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
    Hu X; Luo H; Tan G; Li Y; Qin B
    BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
    Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
    J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
    Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
    Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.
    Yang JM; Chen LP; Wang YJ; Lyu B; Zhao H; Shang ZY; Li J; Fan ZY; Wu SD; Ming X; Li X; Huang SP; Cheng JL
    Chin Med J (Engl); 2020 Jul; 133(14):1639-1648. PubMed ID: 32568867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
    Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
    Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
    Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
    J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study.
    Lian J; Kuang W; Jia H; Lu Y; Zhang X; Ye C; Gu J; Lv Y; Yu J; Zhang Y; Lu X; Zhao Y; Yang D; Wang K; Zhao P; Yu Y; Bai L; Zhang J; Zhang X; Yang Y
    J Med Virol; 2022 Nov; 94(11):5475-5483. PubMed ID: 35836102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
    J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
    Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
    Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.